

PROGRAM

March 28

Session 1. Setting the tone

Chair: Gerald Marti

09:00 – 09:10 Welcome - *A. Wiestner, P. Ghia*

09:10 – 09:40 On the road to CLL - *P. Ghia*

09:40 – 10:05 CLL clonal dynamics - *N. Chiorazzi*

10:05 – 10:30 IG genes in CLL: biological aspects -
K. Stamatopoulos

Session 2. Immunoglobulin gene sequence analysis

Chair: Marie-Paule Lefranc

10:50 – 11:10 Mechanisms of immunoglobulin diversity - *F. Davi*

11:10 – 11:40 From the patient to the sequence: Primers, PCR, Detection of clonality, Sanger sequencing - *L. Sutton*

11:40 – 12:00 IMGT tools for interpretation of IG gene sequence data - *V. Giudicelli*

12:00 – 12:20 Specific challenges in IG gene interpretation and tailored bioinformatics solutions - *A. Hadzidimitriou*

Session 3. Practical exercises: basic

Chair: Laura Rassenti

13:00 – 13:45 Hands-on exercises I
- *K. Stamatopoulos*

13:45 – 14:30 Sequence interpretation
- *K. Stamatopoulos*

Session 4. Practical exercises: advanced

Chair: Diane Jelinek

15:00 – 16:00 Hands-on exercises II
- *A. Agathangelidis*

16:00 – 17:00 Sequence interpretation
- *F. Davi*

Social Program and Reception

March 29

Session 5. The IG as a biomarker and a therapeutic target in CLL

Chair: Paolo Ghia

09:00 – 09:45 Targeting signaling pathways to treat CLL - *A. Wiestner*

10:45 – 10:30 Prognostic considerations
- *R. Rosenquist*

Session 6. New directions - standards

Chair: R. Rosenquist

11:00 – 11:30 NGS IG analysis - basic principles -
A. Langerak

11:30 – 12:00 NGS IG analysis in CLL - prognostication - *F. Davi*

12:00 – 12:30 How to report IG gene sequence data in clinical diagnostics - *L. Sutton*

12:30 – 12:45 The ERIC IG Network
- *A. Chatzidimitriou*

12:45 – 13:00 Wrap up – *P. Ghia, A. Wiestner*

Meeting Location

Clinical Center of the National Institutes of Health, Bethesda, MD



ERIC thanks its supporters!



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*